Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32ISN Blog

Monday, 08 February 2016 10:32

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

By  Macdougall et al.
Rate this item
(0 votes)

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.


Authors: Iain C. Macdougall, Andreas J. Bircher, Kai-Uwe Eckardt, Gregorio T. Obrador, Carol A. Pollock, Peter Stenvinkel, Dorine W. Swinkels, Christoph Wanner, Günter Weiss, Glenn M. Chertow


Reference: Kidney Int Volume 89, Issue 1, January 2016, Pages 28–39; doi:10.1016/j.kint.2015.10.002


Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Event: Other events
  • Year: 2016
  • Members Only: No
Read 240 times Last modified on Monday, 08 February 2016 10:38

Leave your comments

Post comment as a guest

Your comments are subject to administrator's moderation.
terms and condition.
  • No comments found

compact blue

Global Operations Center

Rue des Fabriques 1
1000 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact